


# Using bacteria to target cancer treatment

March 28 2023

---



Engineered EcN bind and retain Cu-YbT specifically via *FyuA*. A) Reaction

mechanism depicting complexation of  $^{64/67}\text{Cu}$  by yersiniabactin (YbT). B) Schematic highlighting FyuA-specific delivery of Cu-YbT radiopharmaceuticals by EcN-based pretargeted cancer theranostic platform. C) Immunoblot confirming FyuA expression by engineered EcN. D) Schematic of EcN constructs used for E) quantitative (regression curve) assessment of FyuA overexpression. F) Dissociation curve of  $^{64}\text{Cu}$ -YbT from EcN-fyuA $\uparrow$ Data in (E) and (F) presented as mean  $\pm$  s.d. ( $n = 3$ ); data in (E) ( $10^9$  cfu) analyzed by one-way ANOVA and Dunnett's T3 multiple comparison test with Brown–Forsythe and Welch's correction,  $\alpha = 0.05$ . \* $p$

Citation: Using bacteria to target cancer treatment (2023, March 28) retrieved 5 May 2024 from <https://medicalxpress.com/news/2023-03-bacteria-cancer-treatment.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.